Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Profit After Tax (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Profit After Tax for 11 consecutive years, with $26806.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Profit After Tax rose 100.79% year-over-year to $26806.0, compared with a TTM value of -$8.5 million through Sep 2025, down 233.69%, and an annual FY2024 reading of $3.6 million, up 128.73% over the prior year.
  • Profit After Tax was $26806.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$2.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $13.5 million in Q1 2024 and bottomed at -$5.8 million in Q3 2023.
  • Average Profit After Tax over 5 years is -$1.7 million, with a median of -$2.3 million recorded in 2022.
  • The sharpest move saw Profit After Tax crashed 385.3% in 2021, then skyrocketed 819.99% in 2024.
  • Year by year, Profit After Tax stood at -$5.8 million in 2021, then skyrocketed by 35.64% to -$3.7 million in 2022, then soared by 61.42% to -$1.4 million in 2023, then plummeted by 195.61% to -$4.2 million in 2024, then skyrocketed by 100.63% to $26806.0 in 2025.
  • Business Quant data shows Profit After Tax for KPRX at $26806.0 in Q3 2025, -$2.2 million in Q2 2025, and -$2.2 million in Q1 2025.